CADTH is inviting stakeholder comments on proposed changes to the patient input template for the CADTH Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR). Patient input is used by CADTH review teams and by the expert committees of the CDR and pCODR programs: the CADTH Canadian Drug Expert Committee (CDEC) or the pCODR Expert Review Committee (pERC). The objective is to help improve the quality of Canadian health technology assessment drug processes.
One will notice the following:
- In response to the comments, CDR has provided a brief explanation, for each section, on how CADTH will use the insights and experiences provided.
- Greater focus on treatment rather than disease.
- Caregiver views are included for each question.
- Updated conflict of interest declaration form, which will be identical across both processes. For both processes, dollar amounts will be redacted from the conflict of interest declaration form when the document is publicly posted on CADTH’s website.
For more information about the proposed changes, please see the CDR and pCODR Patient Input Template.
CADTH welcomes your feedback on the proposed revisions to the patient input templates. From September 12 to October 25, 2016, patient groups are invited to comment on the proposed templates. Please use the feedback form and e-mail to email@example.com. All feedback submitted by the deadline will be carefully considered and used to inform the final templates, targeted for use in December 2016.